Optimizing blood pressure control in hypertension: The need to use ABPM

Blood Pressure

Volumn 22, Issue 2, 2013, Pages 65-72

  Schmieder, Roland E ^a   Lehmann, Marina V ^a   Schmidt, Stephanie ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Ambulatory blood pressure monitoring; Antihypertensive agents; Blood pressure; Hypertension; Masked hypertension; White coat hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; FOLLOW UP; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; HUMANS; HYPERTENSION; PRIMARY HEALTH CARE;

EID: 84875203016     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2012.727253     Document Type: Article

References (65)

1. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. JHypertens. 2007; 25: 1751-1762.
2. Mancia G, Grassi G. Management of essential hypertension. Br Med Bull. 2010; 94: 189-199.
3. Saini M, Shuaib A. Blood pressure lowering and stroke. Expert Rev Neurother. 2010; 10: 225-241.
4. Paramore LC, Halpern MT, Lapuerta P, Hurley JS, Frost FJ, Fairchild DG, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am JManag Care. 2001; 7: 389-398.
5. Oparil S. Hypertension in 2010: New challenges in blood pressure goals and assessment. Nat Rev Cardiol. 2011; 8: 73-75.
6. Parati G, Faini A, Valentini M. Blood pressure variability: Its measurement and signifi cance in hypertension. Curr Hypertens Rep. 2006; 8: 199-204.
7. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010; 375: 938-948.
8. Mancia G, Parati G. Importance of smooth and sustained blood pressure control in preventing cardiovascular morbidity and mortality. Blood Press Suppl. 2001;10(Suppl 3): 26-32.
9. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011; 124: 1727-1736.
10. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003; 348: 2407-2415.
11. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin outcome study. Hypertension. 2005; 46: 156-161.
12. Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: Systematic review. BMJ. 2011; 342: d3621.
13. National Institute for Health and Clinical Excellence. Hypertension: The clinical management of primary hypertension in adults. 2011 [cited 2011 Jan 10]; Available from: http://www.nice.org.uk/nicemedia/live/13561/56007/56007. pdf
14. Ohkubo T, Imai Y, Tsuji I, Nagai K, Ito S, Satoh H, et al. Reference values for 24-hour ambulatory blood pressure monitoring based on aprognostic criterion: The Ohasama Study. Hypertension. 1998; 32: 255-259.
15. Staessen JA, Fagard RH, Lijnen PJ, Thijs L, Van HR, Amery AK. Mean and range of the ambulatory pressure in normotensive subjects from ameta-analysis of 23 studies. Am JCardiol. 1991; 67: 723-727.
16. Mancia G, Sega R, Bravi C, De VG, Valagussa F, Cesana G, et al. Ambulatory blood pressure normality: Results from the PAMELA study. J Hypertens. 1995; 13(12 Pt 1): 1377-1390.
17. Head GA, Mihailidou AS, Duggan KA, Beilin LJ, Berry N, Brown MA, et al. Defi nition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: Prospective cohort study. BMJ. 2010; 340: c1104.
18. Bobrie G, Clerson P, Menard J, Postel-Vinay N, Chatellier G, Plouin PF. Masked hypertension: Asystematic review. J Hypertens. 2008; 26: 1715-1725.
19. Papadopoulos DP, Makris TK. Masked hypertension defi nition, impact, outcomes: Acritical review. JClin Hypertens (Greenwich). 2007; 9: 956-963.
20. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classifi ed on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57: 898-902.
21. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Blunted heart rate dip during sleep and all-cause mortality. Arch Intern Med. 2007; 167: 2116-2121.
22. Parati G, Bilo G. Should 24-h ambulatory blood pressure monitoring be done in every patient with diabetes? Diabetes Care. 2009; 32 Suppl 2: S298-S304.
23. O' Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. JHypertens. 2003; 21: 821-848.
24. O' Brien E, Atkins N, Stergiou G, Karpettas N, Parati G, Asmar R, et al. European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults. Blood Press Monit. 2010; 15: 23-38.
25. O' Brien E, Coats A, Owens P, Petrie J, Padfi eld PL, Littler WA, et al. Use and interpretation of ambulatory blood pressure monitoring: Recommendations of the British hypertension society. BMJ. 2000; 320: 1128-1134.
26. O' Brien E. Twenty-four-hour ambulatory blood pressure measurement in clinical practice and research: Acritical review of atechnique in need of implementation. JIntern Med. 2011; 269: 478-495.
27. Chrysant SG. Treatment of white-coat hypertension. Curr Hypertens Rep. 2000; 2: 412-417.
28. Pierdomenico SD, Cuccurullo F. Prognostic value of whitecoat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: An updated meta analysis. Am J Hypertens. 2011; 24: 52-58.
29. Dawes MG, Bartlett G, Coats AJ, Juszczak E. Comparing the effects of white-coat hypertension and sustained hypertension on mortality in aUK primary care setting. Ann Fam Med. 2008; 6: 390-396.
30. Puchades R, Ruiz-Nodar JM, Blanco F, Rodriguez F, Gabriel R, Suarez C. White-coat hypertension in the elderly. Echocardiographic analysis. Asubstudy of the EPICARDIAN project. Rev Esp Cardiol. 2010; 63: 1377-1381.
31. Messerli FH, Cotiga D. Masked hypertension and whitecoat hypertension: Therapeutic navigation between scylla and charybdis. JAm Coll Cardiol. 2005; 46: 516-517.
32. Kim SG. Clinical implications of ambulatory and home blood pressure monitoring. Korean Circ J. 2010; 40: 423-431.
33. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Longterm risk of mortality associated with selective and combined elevation in offi ce, home, and ambulatory blood pressure. Hypertension. 2006; 47: 846-853.
34. Ogedegbe G, Agyemang C, Ravenell JE. Masked hypertension: Evidence of the need to treat. Curr Hypertens Rep. 2010; 12: 349-355.
35. Stolarz-Skrzypek K, Thijs L, Richart T, Li Y, Hansen TW, Boggia J, et al. Blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. Hypertens Res. 2010; 33: 757-766.
36. Bjorklund K, Lind L, Zethelius B, Andren B, Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation. 2003; 107: 1297-1302.
37. Kabutoya T, Ishikawa J, Hoshide S, Eguchi K, Ishikawa S, Shimada K, et al. Determinants of negative white-coat effect in treated hypertensive patients: The Jichi Morning Hypertension Research (J-MORE) study. Am JHypertens. 2009; 22: 35-40.
38. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Infl uence of circadian time of hypertension treatment on cardiovascular risk: Results of the MAPEC study. Chronobiol Int. 2010; 27: 1629-1651.
39. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension . Circulation. 1990; 81: 528-536.
40. Tsioufi sC, Andrikou I, Thomopoulos C, Syrseloudis D, Stergiou G, Stefanadis C. Increased nighttime blood pressure or nondipping profi le for prediction of cardiovascular outcomes. J Hum Hypertens. 2011; 25: 281-293.
41. Ivanovic BA, Tadic MV, Celic VP. To dip or not to dip? The unique relationship between different blood pressure patterns and cardiac function and structure. JHum Hypertens. 2011 Sep 8. doi:10.1038/jhh.2011.83
42. Cuspidi C, Sala C, Valerio C, Negri F, Mancia G. Nocturnal blood pressure in untreated essential hypertensives. Blood Press. 2011; 20: 335-341.
43. Omboni S, Parati G, Palatini P, Vanasia A, Muiesan ML, Cuspidi C, et al. Reproducibility and clinical value of nocturnal hypotension: Prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation. J Hypertens. 1998; 16: 733-738.
44. Kim BK, Lim YH, Lee HT, Lee JU, Kim KS, Kim SG, et al. Non-dipper pattern is adeterminant of the inappropriateness of left ventricular mass in essential hypertensive patients. Korean Circ J. 2011; 41: 191-197.
45. Syrseloudis D, Tsioufi SC, Aragiannis D, Soulis D, Stefanadi E, Spanos A, et al. The dominant role of the systolic component of nondipping status on target-organ damage in never-treated hypertensives. Am J Hypertens. 2011; 24: 292-298.
46. Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension. 1996; 27: 130-135.
47. Syrseloudis D, Andrikou I, Andrikou E, Dimitriadis K, Stefanadis C. Ambulatory blood pressure monitoring in resistant hypertension. Int J Hypertens. 2011;2011: 285612.
48. Wolf J, Hering D, Narkiewicz K. Non-dipping pattern of hypertension and obstructive sleep apnea syndrome. Hypertens Res. 2010; 33: 867-871.
49. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension. 2011; 57: 3-10.
50. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. JAm Coll Cardiol. 2011; 58: 1165-1173.
51. Li Y, Thijs L, Hansen TW, Kikuya M, Boggia J, Richart T, et al. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension. 2010; 55: 1040-1048.
52. Israel S, Israel A, Ben-Dov IZ, Bursztyn M. The morning blood pressure surge and all-cause mortality in patients referred for ambulatory blood pressure monitoring. Am JHypertens. 2011; 24: 796-801.
53. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as apredictor of silent and clinical cerebrovascular disease in elderly hypertensives: Aprospective study. Circulation. 2003; 107: 1401-1406.
54. Kario K, Yano Y, Matsuo T, Hoshide S, Eguchi K, Shimada K. Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients. Eur Heart J. 2011; 32: 574-580.
55. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, et al. Prognostic signifi cance for stroke of amorning pressor surge and anocturnal blood pressure decline: The Ohasama study. Hypertension. 2006; 47: 149-154.
56. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfi eld MJ, et al. Reappraisal of European guidelines on hypertension management: AEuropean Society of Hypertension Task Force document. J Hypertens. 2009; 27: 2121-2158.
57. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338: b1665.
58. Iqbal P, Stevenson L. Cardiovascular outcomes in patients with normal and abnormal 24-hour ambulatory blood pressure monitoring. Int JHypertens. 2010;2011: 786912.
59. Elliott HL. 2 4-Hour blood pressure control: Its relevance to cardiovascular outcomes and the importance of long-acting antihypertensive drugs. J Hum Hypertens. 2004; 18: 539-543.
60. White WB. Importance of blood pressure control over a 24-hour period. J Manag Care Pharm. 2007; 13(8 Suppl B): 34-39.
61. Neutel JM. The importance of 24-h blood pressure control. Blood Press Monit. 2001; 6: 9-16.
62. Lowy A, Munk VC, Ong SH, Burnier M, Vrijens B, Tousset EP, et al. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: Role of duration of drug action. Int JClin Pract. 2011; 65: 41-53.
63. Oparil S, Kjeldsen SE, Narkiewicz K, Hedner T. Blood pressure variability: Emerging role in risk assessment and therapeutics. Blood Press. 2010; 19: 209-211.
64. Schmieder RE, Ruilope LM. Blood pressure control in patients with comorbidities. JClin Hypertens (Greenwich). 2008; 10: 624-631.
65. Parati G, Schumacher H, Bilo G, Mancia G. Evaluating 24-h antihypertensive effi cacy by the smoothness index: Ameta-analysis of an ambulatory blood pressure monitoring database. JHypertens. 2010; 28: 2177-2183.